Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Authors
Van Akkooi, A. C. J.Hauschild, A.
Long, G. V.
Mandala, M.
Kicinski, M.
Govaerts, A. S.
Klauck, I.
Ouali, M.
Lorigan, Paul C
Eggermont, A. M. M.
Affiliation
Surgical Oncology Dept., Melanoma Institute Australia, Wollstonecraft, NSW, AustraliaIssue Date
2022
Metadata
Show full item recordCitation
Van Akkooi ACJ, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Annals of Oncology. 2022 Nov;38(9):S1617-S8. PubMed PMID: WOS:000897943700465.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.10.494Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.10.494Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.10.494